Pranlukast

CAT: 0804-HY-B0290-01Size: 100 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0290-01Size:100 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
CAS Number
[103177-37-3]
Product Name Alternative
ONO-1078
UNSPSC
12352005
Hazard Statement
H315, H319
Target
Endogenous Metabolite; Leukotriene Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/pranlukast.html
Purity
99.61
Solubility
DMSO : 33.33 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL
Smiles
O=C(NC1=C2C(C(C=C(C3=NNN=N3)O2)=O)=CC=C1)C4=CC=C(OCCCCC5=CC=CC=C5)C=C4
Molecular Formula
C27H23N5O4
Molecular Weight
481.50
Precautions
H315, H319
References & Citations
[1]Obata T, et al. In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes in isolated guinea pig tissues. Jpn J Pharmacol. 1992 Nov;60 (3) :227-37.|[2]Fang SH, et al. Nuclear translocation of cysteinyl leukotriene receptor 1 is involved in oxygen-glucose deprivation-induced damage to endothelial cells. Acta Pharmacol Sin. 2012 Dec;33 (12) :1511-7.|[3]Ogata M, et al. Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pretreated mice. Infect Immun. 1992 Jun;60 (6) :2432-7.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
LTC4/CysLT2; LTD4/CysLT1; LTE4

Alternative Products

CatalogName
C16511Pranlukast
MF-0015950-01Pranlukast hemihydrate
GP8160-50mgPranlukast hydrate
sc-219634Pranlukast-d5

Popular Products